ANGLE PLC (LON:AGL, OTCQX:ANPCY) said its liquid biopsy system was used in important work to isolate single circulating tumour cells.
The company’s Parsortix system was used in harness with a device called CellCelector, a micromanipulator.
The idea behind the project, carried out by a team of cancer researchers and clinicians in Duesseldorf, was to assess the “heterogeneity” of the disease.
In layman’s terms, they wanted to know what determined the basis of different strains of the same cancer – in this case breast cancer.
By isolating cancer cells the Duesseldorf team was able to detect varying gene expression between the individual CTCs as well as demonstrating that changes in the patient's HER-2 expression can be detected.
Human epidermal growth factor receptor 2, or HER-2, plays an important role in the development of breast cancer.
The detailed results of the research were published in the peer-reviewed journal Cancers.
ANGLE’s chief executive Andrew Newland said: "This new workflow provides a simple and effective approach to single cell CTC analysis, which is a developing area of research use for the Parsortix system.
“Investigation of gene expression and HER-2 status in breast cancer will be an important application of Parsortix following FDA [US Food & Drug Administration] clearance."
The shares rose 1% to 71.75p
---adds share price---